TY - JOUR
T1 - Current Approaches to Philadelphia Chromosome–Positive B-Cell Lineage Acute Lymphoblastic Leukemia
T2 - Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant
AU - Kim, Kunhwa
AU - Jabbour, Elias
AU - Short, Nicholas J.
AU - Kebriaei, Partow
AU - Kantarjian, Hagop
AU - Ravandi, Farhad
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/8
Y1 - 2021/8
N2 - Purpose of Review: Over the past two decades, tyrosine kinase inhibitors (TKIs) have changed the management of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), and this has led to significant improvement in their outcome. In this review, we will provide an overview of the current understanding of treatment of Ph+ ALL focusing on TKIs, alloHSCT, and novel therapies. Recent findings: The advent of more potent TKIs and the novel therapeutic options including blinatumomab, inotuzumab ozogamicin, and CD19 CAR-T therapy has changed the role of allogeneic hematopoietic stem cell transplant (alloHSCT) and intensive chemotherapy. To avoid toxicity from the historical treatment strategies, a more individualized, targeted approach to therapy including detection and monitoring of measurable residual disease (MRD) has become of interest. Summary: The treatment of patients with Ph+ ALL has been rapidly evolving with a more individualized, targeted treatment and use of TKIs and novel therapy.
AB - Purpose of Review: Over the past two decades, tyrosine kinase inhibitors (TKIs) have changed the management of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), and this has led to significant improvement in their outcome. In this review, we will provide an overview of the current understanding of treatment of Ph+ ALL focusing on TKIs, alloHSCT, and novel therapies. Recent findings: The advent of more potent TKIs and the novel therapeutic options including blinatumomab, inotuzumab ozogamicin, and CD19 CAR-T therapy has changed the role of allogeneic hematopoietic stem cell transplant (alloHSCT) and intensive chemotherapy. To avoid toxicity from the historical treatment strategies, a more individualized, targeted approach to therapy including detection and monitoring of measurable residual disease (MRD) has become of interest. Summary: The treatment of patients with Ph+ ALL has been rapidly evolving with a more individualized, targeted treatment and use of TKIs and novel therapy.
KW - ALL
KW - Minimal residual disease
KW - Philadelphia chromosome
KW - Stem cell transplant
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85108001632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108001632&partnerID=8YFLogxK
U2 - 10.1007/s11912-021-01086-y
DO - 10.1007/s11912-021-01086-y
M3 - Review article
C2 - 34125415
AN - SCOPUS:85108001632
SN - 1523-3790
VL - 23
JO - Current oncology reports
JF - Current oncology reports
IS - 8
M1 - 95
ER -